254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity

Autor: Stipan Jonjic, Ofer Mandelboim, Anas Atieh, Akram Obiedat, Guy Cinamon, Tihana Lenac Rovis, Paola Kucan Brlic, Lea Hirsl, Keren Paz, Pini Tsukerman

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Externí odkaz: https://doaj.org/article/e4e7b326de894533a91180eca87bdd91

Abstract 6657: Phase I trial of first-in-class anti-PVR mAb NTX1088: Restoration of DNAM1 expression as MOA for enhanced antitumor immunity

Autor: Anas Atieh, Akram Obiedat, Alon Vitenshtein, Guy Cinamon, Keren Paz, Tihana lenac, Paola Kucan, Marija Mazor, Ofer Mandelboim, Stipan Jonji, Pini Tsukerman

Publikováno v: Cancer Research. 83:6657-6657

NTX1088, a first-in-class anti-PVR (CD155) monoclonal antibody (mAb), is currently evaluated in a Phase 1, open-label, multi-center study (NCT05378425), initiated at MD Anderson Cancer center. Study objectives are safety, dose-finding, and efficacy w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb26b327a488a13cee12264095cc4032
https://doi.org/10.1158/1538-7445.am2023-6657

Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity

Autor: Pini Tsukerman, Anas Atieh, Akram Obeidat, Keren Paz, Guy Cinamon, Tihana Lenac Rovis, Paola Kucan Brlic, Lea Hirsl, Stipan Jonjić, Ofer Mandelboim

Publikováno v: Cancer Immunology Research. 10:P075-P075

The poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies immune function through multiple mechanisms. Increased levels of PVR exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbf732cdd4d08e917f2aedf27d976ed0
https://doi.org/10.1158/2326-6074.tumimm21-p075

Abstract P102: NTX-1088, A potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity

Autor: Pini Tsukerman, Anas Atieh, Akram Obeidat, Keren Paz, Guy Cinamon, Tihana Lenac Roviš, Lea Hirsl, Paola Kucan Brilc, Stipan Jonjic, Ofer Mandelboim

Publikováno v: Molecular Cancer Therapeutics. 20:P102-P102

The poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies immune function through multiple mechanisms. Increased levels of PVR exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66cf0c3b623d55dcecc694bc5edb8f6d
https://doi.org/10.1158/1535-7163.targ-21-p102

Talin1 is required for integrin-dependent B lymphocyte homing to lymph nodes and the bone marrow but not for follicular B-cell maturation in the spleen

Autor: Yael Gore, Guy Cinamon, Ronen Alon, Idit Shachar, Gera Goverse, Raanan Margalit, Valentin Grabovsky, Reina E. Mebius, Sara W. Feigelson, Doron Melamed, Eugenia Manevich-Mendelson, David R. Critchley, Susan J. Monkley

Publikováno v: Manevich-Mendelson, E, Grabovsky, V, Feigelson, S W, Cinamon, G, Gore, Y, Goverse, G, Monkley, S J, Margalit, R, Melamed, D, Mebius, R E, Critchley, D R, Shachar, I & Alon, R 2010, ' Talin1 is required for integrin-dependent B lymphocyte homing to lymph nodes and the bone marrow but not for follicular B-cell maturation in the spleen ', Blood, vol. 116, no. 26, pp. 5907-5918 . https://doi.org/10.1182/blood-2010-06-293506
Blood, 116(26), 5907-5918. American Society of Hematology

Talin1 is a key integrin coactivator. We investigated the roles of this cytoskeletal adaptor and its target integrins in B-cell lymphogenesis, differentiation, migration, and function. Using CD19 Cre-mediated depletion of talin1 selectively in B cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024cda190b034fdf5f9e1af0aa75732a
https://doi.org/10.1182/blood-2010-06-293506